9 Sources of evidence considered by the Committee

9 Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the Southampton Health Technology Assessments Centre:

  • Hartwell D, Cooper K et al, The clinical and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people, January 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I. Manufacturers/sponsors:

  • Merck Sharp and Dohme

  • Roche Products

II. Professional/specialist and patient/carer groups:

  • British Liver Trust

  • British Society of Gastroenterology

  • Children's Liver Disease Foundation

  • Hepatitis C Trust

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on peginterferon alfa and ribavirin by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Rosie Hague, clinical expert, Consultant in Paediatric Infectious Diseases and Immunology, nominated by Healthcare Improvement Scotland – clinical specialist

  • Professor Deirdre Kelly, Professor of Paediatric Hepatology, nominated by Merck, Sharp and Dohme – clinical specialist

  • Susan McRae, nominated by The Hepatitis Trust – patient expert

D. Representatives from the following manufacturers/sponsors attended the Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Merck Sharp and Dohme

  • Roche Products

  • National Institute for Health and Care Excellence (NICE)